Zidesamtinib received FDA approval for patients with ROS1+ NSCLC after a prior ROS1 inhibitor, based on the ARROS1 trial which demonstrated a 44% response rate. A study in JCO found that for extensive-stage SCLC (ES-SCLC) with brain-only progression, continuing the original systemic therapy with brain radiotherapy may yield better survival than switching regimens. DLL3-directed therapies are also an emerging topic in SCLC, with discussion focused on optimal sequencing.
“Zidesamtinib receives for pts with ROS1+ NSCLC after a prior ROS1 inhibitor. Approval based on the ARROS1 trial that showed RR 44% after prior TKI with 1y DOR rate 69%.”
— @StephenVLiu · Zidesamtinib approval · View post ↗📌 Amplified by @KolPulseAI
“For brain-only progression in ES-SCLC, continuing the original systemic therapy with brain radiotherapy may yield better survival than switching regimens”
— @M_Torasawa · SCLC brain progression · View post ↗
“DLL3-directed therapies have officially arrived in SCLC. The question is no longer IF to use them...but WHEN.”
— @lungoncdoc · DLL3 in SCLC · View post ↗📌 Amplified by @KolPulseAI
“Top 5 questions still shaping the role of RT in oligometastatic NSCLC: 1. Who? 2. When? 3. Where? 4. How much? 5. Which biology?”
— @lungoncdoc · RT in oligometastatic NSCLC · View post ↗A study of gedatolisib plus trastuzumab in pretreated, PIK3CA-mutated, HER2+ metastatic breast cancer (MBC) yielded an ORR of 43% and a PFS of 6 months, with stomatitis as a key toxicity. Additionally, the EN-SEMBLE study suggests T-DXd rechallenge may be effective in select HER2+ mBC patients who discontinued for reasons other than progressive disease. The breast oncology community is also noting a German Group study in JCO comparing neoadjuvant trastuzumab/pertuzumab plus endocrine therapy against chemotherapy for HR+/HER2+ early breast cancer.
“gedatolisib + trastuzumab yielded an ORR of 43% and PFS 6 months for pretreated, PIK3CAm, HER2+ MBC. Key toxicity: stomatitis.”
— @PTarantinoMD · gedatolisib in HER2+ MBC · View post ↗📌 Amplified by @KolPulseAI
“EN-SEMBLE: T-DXd rechallenge may remain effective in selected patients with HER2+ mBC, particularly those who discontinued initial T-DXd for reasons other than PD.”
— @dr_yakupergun · T-DXd rechallenge · View post ↗
“Amazing how far we've come in improving survival, while balancing QOL for women - great study by the German Group.”
— @ramsedhom · Neoadjuvant HR+/HER2+ EBC · View post ↗A meta-analysis of three RCTs shows adjuvant aspirin improved DFS (HR 0.61) in colorectal cancer patients with PIK3CA exon 9/20 mutations, though the ASCOLT trial showed no overall benefit in a broader PIK3CA-mutant population. Separately, a real-world study of modified perioperative FLOT in resectable gastric/GEJ adenocarcinoma (n=29) found an 88% R0 resection rate and a 16% pCR.
“🧬 Adj aspirin in CRC: precision matters ❌ ASCOLT: no DFS benefit overall in PIK3CAmt / COX-2 overexp. 📊 Meta-analysis (3 RCTs): ✅ PIK3CAmt exon 9/20: ⬆️ DFS (HR 0.61) 🎯 Aspirin may benefit a molecularly selected subgroup, not all patients.”
— @DraMartinezLago · Adjuvant Aspirin in CRC · View post ↗
“Our multi-institutional real-world study just out in J Gastrointest Oncol (PMID: 42434291) Modified perioperative FLOT in resectable gastric/GEJ adenocarcinoma (n=29; median age 66; 59% gastric, 34% GEJ): • Curative-intent resection 86%, R0 88%, pCR 16% • Median follow-up 30.3”
— @sonbol_bassam · Modified FLOT in Gastric/GEJ Cancer · View post ↗
“Efficacy of Stereotactic Body Radiation Therapy in Recurrent Intrahepatic Cholangiocarcinoma”
— @Applied_RadOnc · SBRT for Cholangiocarcinoma · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
A new quality-of-life analysis of the NRG/RTOG 0534 SPPORT trial for salvage prostate radiotherapy found that adding short-course ADT and pelvic nodal radiation therapy resulted in meaningful short-term toxicity but little persistent harm to quality of life. Additionally, the new EAU 2026 Prostate Cancer Guidelines recommend early salvage RT for biochemical recurrence, establish PSMA PET as the preferred imaging modality, and state ADT alone is no longer sufficient for most mHSPC patients. In bladder cancer, discussions are focusing on drug development for BCG-unresponsive disease, including new data for Detalimogene.
“For salvage prostate RT, short-course ADT and pelvic nodal RT improve disease control, but what is the patient-reported cost? The answer: meaningful short-term toxicity, but little evidence of persistent incremental QOL harm.”
— @jryckman3 · NRG/RTOG 0534 SPPORT QOL · View post ↗📌 Amplified by @KolPulseAI
“EAU 2026 Prostate Cancer Guidelines are here. Key updates: ✅ Early salvage RT for BCR ✅ PSMA PET as preferred imaging ✅ ADT alone is no longer enough for most mHSPC patients ✅ Molecular testing guides precision therapy ✅ Triplet therapy for appropriate patients ✅ Prostate”
— @K_Yadavir · EAU 2026 Prostate Cancer Guidelines · View post ↗
“Ashish Kamat, MD, joins Brian and Tom to discuss the recent FDA meeting on bladder cancer drug development, evolving approval pathways, and promising new data on detalimogene for BCG-unresponsive NMIBC.”
— @Uromigos · Bladder Cancer Drug Development · View post ↗A phase 1 trial of the FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma was published in Nature Medicine. Additionally, the community is noting a new CIBMTR analysis on the time to and depth of response following idecabtagene vicleucel (ide-cel).
“Here is a table for available CART & BsAb in earlier lines for Myeloma. Touched on this during our “Challenging Cases” in Myeloma”
— @OncBrothers · CAR-T & Bispecifics summary · View post ↗📌 Amplified by @KolPulseAI
“New in @NatureMedicine from @JoshuaRichterMD and colleagues: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial”
— @TischCancer · Cevostamab Phase 1 data · View post ↗
“So proud of our amazing @CCF_IMCHIEFS resident, soon to be @MayoHemeOnc fellow @utkarshgoel08 for publishing @CIBMTR analysis on time to best response and depth of response post idecel #CART #mmsm”
— @khouri_jack · Ide-cel response analysis · View post ↗The Phase 3 TRANSFORM-1 study evaluated the efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis. Additionally, a matching-adjusted indirect treatment comparison was published assessing pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis. A Phase 2 study of ruxolitinib plus azacitidine for patients with MDS/MPNs was also highlighted.
“👉#TRANSFORM-1 Phase 3 study: Efficacy and safety of #navitoclax plus ruxolitinib in patients with untreated myelofibrosis”
— @doctorpemm · TRANSFORM-1 in Myelofibrosis · View post ↗“👉Full article: Efficacy of #pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison”
— @doctorpemm · Myelofibrosis Treatment Comparison · View post ↗
“⭐️ FLT3 Inhibitors in #AML @Daver_Leukemia discusses w/@OncBrothers when to test for targetable mutations in AML + different types of FLT3 mutations (ITD vs TKD)”
— @OncUpdates · FLT3 Inhibitors in AML · View post ↗